Trial
NCT01562873
Ruxolitinib in Patients With Breast Cancer
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Dana-Farber Cancer Institute
Collaborators
—
Condition
Breast Cancer
Intervention
Ruxolitinib
Why stopped
Not enough responses to continue treatment.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-02-23